Table 4 Trial outcome measures
Primary outcome | • Proportion of clients receiving 80 % or more of their scheduled benzathine penicillin G (BPG) injections over the 12-month intervention period, compared with the pre-intervention period |
Secondary outcomes | • The proportion of scheduled injections that a client receives in a 12-month period • The average number of days at risk. ‘Days at risk’ is the number of days over 28 days between scheduled injections in a month. For clients on 3-weekly injections, ‘Days at risk’ is the number of days over 21 days between scheduled injections • Proportion of clients receiving at least 90 % of scheduled BPG injections over a minimum 12-month period • Proportion of clients receiving 50–79 % and <50 % of scheduled BPG injections over a minimum 12 month period • Recurrence rate and proportion of ARF episodes that are recurrences, compared to non-participating communities and to the whole jurisdiction • Impact of the intervention on RHD clients’ experience of care including their perception and understanding of the disease and its management • Improvement in delivery of other services for RHD clients • Effect of the programme on delivery of other routine services |